Evidence map›Paper›PMID 42870929›Full record

ArticleTranslational lung cancer research2026

Retrospective real-world associations between

Yameng Cui, Shaozhang Zhou, Zheng Liu, Qichuan Wang, Liuchun Wang, Yanhong Shang, Jinghao Jia, Hongjiang Yu, Jiangyan Zhang, Zihui An and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yameng CuiTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Shaozhang ZhouDepartment of Respiratory Oncology, Guangxi Medical University Cancer Hospital, Nanning, China.
Zheng LiuDepartment of Oncology Three, Handan Central Hospital, Handan, China.
Qichuan WangDepartment of Lung Cancer, Nanyang Second General Hospital, Nanyang, China.
Liuchun WangDepartment of Pulmonary Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Yanhong ShangDepartment of Oncology, Affiliated Hospital of Hebei University, Baoding, China.
Jinghao JiaDepartment of Oncology, Affiliated Hospital of North China University of Science and Technology, Tangshan, China.
Hongjiang YuDepartment of Oncology, Tongliao City Hospital, Tongliao, China.
Jiangyan ZhangNanjing Geneseeq Technology Inc., Nanjing, China.
Zihui AnDepartment of Oncology, The First Hospital of Qinhuangdao, Qinhuangdao, China.
Zhansheng JiangTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Junli CaoDepartment of Oncology, The First Hospital of Qinhuangdao, Qinhuangdao, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Furmonertinib, a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has shown promising efficacy in Methods: This retrospective multicenter real-world study enrolled patients with unresectable stage IIIB/C-IV Results: A total of 139 patients were included, among whom 64 harbored Conclusions: This retrospective real-world cohort suggests that

Indexed as

EGFR mutation subtypesFurmonertinibnon-small cell lung cancer (NSCLC)survival

Identifiers

PMID42870929
PMCPMC13657901

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.